Eltrombopag 12.5 mg (DrugBank: Eltrombopag)
5 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
60 | 再生不良性貧血 | 1 |
63 | 特発性血小板減少性紫斑病 | 0 |
65 | 原発性免疫不全症候群 | 0 |
284 | ダイアモンド・ブラックファン貧血 | 0 |
285 | ファンコニ貧血 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02148133 (ClinicalTrials.gov) | July 23, 2014 | 22/5/2014 | A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia | A Non-randomized, Open-label, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia | Cytopaenia | Drug: Eltrombopag 12.5 mg;Drug: Eltrombopag 25 mg | Novartis Pharmaceuticals | NULL | Completed | 18 Years | 79 Years | All | 21 | Phase 2 | Japan |